Quest Diagnostics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DGX and other ETFs, options, and stocks.

About DGX

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments.

CEO

James E. Davis

CEOJames E. Davis

Employees

57,000

Employees57,000

Headquarters

Secaucus, New Jersey

HeadquartersSecaucus, New Jersey

Founded

1967

Founded1967

Employees

57,000

Employees57,000

DGX Key Statistics

Market cap

23.29B

Market cap23.29B

Price-Earnings ratio

23.10

Price-Earnings ratio23.10

Dividend yield

1.56%

Dividend yield1.56%

Average volume

831.19K

Average volume831.19K

High today

$211.00

High today$211.00

Low today

$208.66

Low today$208.66

Open price

$209.31

Open price$209.31

Volume

28.60K

Volume28.60K

52 Week high

$219.20

52 Week high$219.20

52 Week low

$165.30

52 Week low$165.30

Stock Snapshot

As of today, Quest Diagnostics(DGX) shares are valued at $210.41. The company's market cap stands at 23.29B, with a P/E ratio of 23.10 and a dividend yield of 1.56%.

During the trading session on 2026-07-20, Quest Diagnostics(DGX) shares reached a daily high of $211.00 and a low of $208.66. At a current price of $210.41, the stock is +0.8% higher than the low and still -0.3% under the high.

Trading volume for Quest Diagnostics(DGX) stock has reached 28.6K, versus its average volume of 831.19K.

The stock's 52-week range extends from a low of $165.30 to a high of $219.20.

DGX News

Simply Wall St 13h

Quest Diagnostics Expands Oncology Test Access, Is The Stock Fully Valued?

Advertisement Why Quest Diagnostics Stock Is Back in Focus Quest Diagnostics (DGX) is back on investor watchlists after the company moved to integrate its Hay...

Simply Wall St 3d

The Bull Case For Quest Diagnostics Could Change Following Oncology Test Integration Into OncoEMR - Learn Why

Quest Diagnostics Incorporated recently integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumors into Flatiron Healt...

TipRanks 4d

Buy Rating Reaffirmed on Quest Diagnostics as ACA-Related Risks Seen as Manageable and Earnings Resilient

Barclays analyst Luke Sergott maintained a Buy rating on Quest Diagnostics yesterday and set a price target of $230.00. TipRanks has entered a new arena in the...

Analyst ratings

48%

of 21 ratings

Buy

47.6%

Hold

47.6%

Sell

4.8%

More DGX News

TipRanks 5d

HCA preannouncement negative for Quest, Labcorp, says Barclays

Barclays views HCA Healthcare’s (HCA) preannouncement on Affordable Care Act coverage lost during Q2 is a negative read-through for Quest Diagnostics (DGX) and...

People also own

Based on the portfolios of people who own DGX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.